Momentum Bioscience - aVenture Asset Manager Research
Momentum Bioscience
Operating Status: Operating
Momentum Bioscience: Rapid, enzyme-based pathogen detection in blood and sterile fluids.
Location
Reading, Berkshire, GB
Founded
2005
Momentum Bioscience specializes in developing rapid pathogen detection technology, focusing on enzyme-mediated amplification solutions for blood and sterile fluids. Their flagship product, SepsiSTAT®, provides identification and antibiotic susceptibility testing results directly from blood samples in hours, addressing the critical need for faster sepsis diagnosis and targeted treatment.
The company's innovative approach aims to reduce mortality risks and healthcare burdens associated with sepsis and bloodstream infections. Momentum Bioscience has invested in Imaginab, demonstrating their commitment to advancing medical imaging technologies. Their investment strategy appears to include early-stage funding, with participation in Series A rounds.
Momentum Bioscience - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies1
Current Portfolio Count1
Top Investment Stages
Series A1 (100.0%)
Stage Mix
Series A 100%
Concentration shown as share of disclosed investments by stage.
